H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) on Tuesday, setting a price target of $31, which is approximately 149.80% above the present share price of $12.41.
Burns expects Atara Biotherapeutics to post earnings per share (EPS) of -$0.91 for the third quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Atara Biotherapeutics, with an average price target of $50.
The analysts price targets range from a high of $78 to a low of $31.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $3.87 million and a net profit of -$84 million. The company's market cap is $1.05 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of 0.0% and a 29.50% success rate.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.